Log In
BCIQ
Print this Print this
 

Stempeucel

  Manage Alerts
Collapse Summary General Information
Company Cipla Ltd.
DescriptionEx vivo expanded adult allogeneic mesenchymal stem cells derived by using a pooling technology from multiple bone marrow donor samples
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPhase II
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat critical limb ischemia due to thromboangiitis obliterans (Buerger's disease)
Regulatory Designation EU - Orphan Drug (Treat critical limb ischemia due to thromboangiitis obliterans (Buerger's disease))
PartnerManipal Education and Medical Group International India Pvt. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today